PDCD1 and neoplasm: Thus far, pembrolizumab is the only FDA-approved immune checkpoint inhibitor (ICI) for metastatic TNBC, which blocks programmed cell death protein 1 (PD-1) to enhance the T-cell-mediated anti-tumor responses [12].